trending Market Intelligence /marketintelligence/en/news-insights/trending/UF_5lrs89s64DSygMv6dEA2 content esgSubNav
In This List

Sapporo Clinical Laboratory fiscal Q3 profit falls YOY

Blog

Using ESG Analysis to Support a Sustainable Future

Video

S&P Capital IQ Pro | Powered by Expert Insights

Blog

Q&A: Streamlining Analytics for TCFD Reporting

Blog

Evergrande and the wider impact: a sentiment analytics based perspective


Sapporo Clinical Laboratory fiscal Q3 profit falls YOY

Sapporo Clinical Laboratory Inc. said its normalized net income for the fiscal third quarter ended Dec. 31, 2014, came to ¥36.46 per share, a decrease of 19.4% from ¥45.24 per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥136.9 million, a decline of 24.0% from ¥180.0 million in the year-earlier period.

The normalized profit margin declined to 3.1% from 4.2% in the year-earlier period.

Total revenue rose year over year to ¥4.35 billion from ¥4.31 billion, and total operating expenses rose from the prior-year period to ¥4.14 billion from ¥4.02 billion.

Reported net income declined 19.9% on an annual basis to ¥133.0 million, or ¥35.43 per share, from ¥166.0 million, or ¥41.72 per share.

As of Feb. 13, US$1 was equivalent to ¥118.68.